WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its second quarter 2024 financial results and corporate update for Thursday, August 1, 2024. The schedule for the press release and conference call/webcast are as follows: •Q2 2024 Press Release:Thursd ...